MCC
SABS icon

Money Concepts Capital’s SAB Biotherapeutics SABS Stock Holding History

Money Concepts Capital’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-25
Closed -$147 – 2445
2022
Q4 		$147 Buy
+25
New +$228 ﹤0.01% 3124
2022
Q2 		– Sell
-25
Closed -$1K – 2428
2022
Q1 		$1K Buy
+25
New +$1.15K ﹤0.01% 2601

Other funds holding SABS

FPB
First PREMIER Bank Sioux Falls, South Dakota $619M AUM 20.21% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
V
Veritable Wilmington, Delaware $6.46B AUM 17.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
IFAM
Institutional & Family Asset Management Fort Collins, Colorado $654M AUM 12.29% 1-Year Est. Return
MC
Meteora Capital Boca Raton, Florida $1.36B AUM 21.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Money Concepts Capital's SABS Position: Q1 2023 in Review

Money Concepts Capital sold out of SAB Biotherapeutics (SABS) in Q1 2023, closing a stake of 25 shares — an estimated $147 sold.

Money Concepts Capital first reported a position in SABS in Q1 2022 and held it in 2 quarters. The position peaked at $1K in Q1 2022. 39 funds tracked by Wall St. Rank hold SABS as of Q1 2023.

  • Money Concepts Capital reported no remaining SAB Biotherapeutics position as of Q1 2023 after selling out during the quarter.
  • Money Concepts Capital sold 25 SAB Biotherapeutics shares in Q1 2023, an estimated $147.
  • Money Concepts Capital first reported a position in SAB Biotherapeutics in Q1 2022 and held it in 2 quarters.
  • Money Concepts Capital's SAB Biotherapeutics position peaked at $1K in Q1 2022.
  • 39 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q1 2023.

Based on Money Concepts Capital's 13F filing for Q1 2023, filed 1 May 2023.